

Contents

HIGHLIGHTS OF PRESCRIBING INFORMATION	1
FULL PRESCRIBING INFORMATION: CONTENTS*	2
FULL PRESCRIBING INFORMATION	3
1 INDICATIONS AND USAGE	3
2 DOSAGE AND ADMINISTRATION	3
2.1 Important Preparation and Administration Instructions	3
2.2 Preparation and Administration Instructions for the Approved Routes of Administration	3
2.3 Dosage Recommendations	4
2.4 Dosage Modifications for Drug Interactions	4
2.5 Instructions for Mixing Garzulys with Other Insulins	4
3 DOSAGE FORMS AND STRENGTHS	4
4 CONTRAINDICATIONS	4
5 WARNINGS AND PRECAUTIONS	4
5.1 Never Share a Garzulys Prefilled Pen between Patients	4
5.2 Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen	5
5.3 Hypoglycemia	5
5.4 Hypoglycemia Due to Medication Errors	5
5.5 Hypersensitivity Reactions	5
5.6 Hypokalemia	6
5.7 Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists	6
5.8 Hyperglycemia and Ketoacidosis Due to Insulin Pump Device Malfunction	6
6 ADVERSE REACTIONS	6
6.1 Clinical Trials Experience	6
6.2 Immunogenicity	8
6.3 Post Marketing Experience	8
7 DRUG INTERACTIONS	8
8 USE IN SPECIFIC POPULATIONS	9
8.1 Pregnancy	9
8.2 Lactation	10
8.4 Pediatric Use	10
8.5 Geriatric Use	10
8.6 Renal Impairment	10

8.7 Hepatic Impairment	11
10 OVERDOSAGE	11
11 DESCRIPTION	11
12 CLINICAL PHARMACOLOGY	11
12.1 Mechanism of Action	11
12.2 Pharmacodynamics	11
12.3 Pharmacokinetics	13
13 NONCLINICAL TOXICOLOGY	14
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility	14
13.2 Animal Toxicology and/or Pharmacology	15
14 CLINICAL STUDIES	15
14.1 Overview of Clinical Studies	15
14.2 Clinical Studies in Adult and Pediatric Patients with Type 1 Diabetes with Subcutaneous Injections	15
14.3 Clinical Studies in Adults with Type 2 Diabetes with Subcutaneous Injections	16
14.4 Clinical Studies in Adults and Pediatrics with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion (CSII) by External Pump	16
14.5 Clinical Studies in Adults with Type 2 Diabetes Using Continuous Subcutaneous Insulin Infusion (CSII) by External Pump	17
16 HOW SUPPLIED/STORAGE AND HANDLING	18
16.1 How Supplied	18
16.2 Recommended Storage	18
17 PATIENT COUNSELING INFORMATION	19

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use GARZULYS safely and effectively. See full prescribing information for GARZULYS.

GARZULYS™ (insulin aspart-fsan) injection, for subcutaneous or intravenous use
Initial U.S. Approval: YYYY

GARZULYS (insulin aspart-fsan) is biosimilar* to NOVOLOG (insulin aspart).

INDICATIONS AND USAGE

Garzulys is rapid acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus (1).

DOSAGE AND ADMINISTRATION

- See Full Prescribing Information for important preparation, administration, and dosage instructions (2.1, 2.2, 2.3, 2.4, 2.5).
- **Subcutaneous injection (2.2):**
 - Inject subcutaneously within 5-10 minutes before a meal into the abdominal area, thigh, buttocks or upper arm.
 - Rotate injection sites within the same region from one injection to the next to reduce risk of lipodystrophy and localized cutaneous amyloidosis.
 - Should generally be used in regimens with an intermediate- or long-acting insulin.
- **Continuous Subcutaneous Infusion (Insulin Pump) (2.2):**
 - Refer to the insulin infusion pump user manual to see if Garzulys or NOVOLOG can be used with the insulin pump, in which case Garzulys can be used with the pump. Use in accordance with the insulin pump instructions for use.
 - Administer by continuous subcutaneous infusion using an insulin pump in a region recommended in the instructions from the pump manufacturer.
 - Rotate the injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis.
 - Do not mix with other insulins or diluents in the pump.
- **Intravenous Administration (2.2):**
 - Dilute Garzulys to concentrations from 0.05 unit per mL to 1 unit per mL insulin aspart-fsan in infusion systems using polypropylene infusion bags.
 - Garzulys is stable in infusion fluids such as 0.9% Sodium Chloride Injection, USP.
- Individualize and adjust the dosage of Garzulys based on route of administration, the individual's metabolic needs, blood glucose monitoring results and glycemic control goal (2.4).
- Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), changes in renal or hepatic function or during acute illness (2.4).

DOSAGE FORMS AND STRENGTHS

Injection: 100 units/mL (U-100) of insulin aspart-fsan available as:

- 10 mL multiple-dose vial (3)
- 3 mL single-patient-use prefilled pen (3)

CONTRAINDICATIONS

- During episodes of hypoglycemia (4).
- Hypersensitivity to insulin aspart products or any of the excipients in Garzulys.

WARNINGS AND PRECAUTIONS

- *Never share a Garzulys prefilled pen, needles or syringes between patients, even if the needle is changed (5.1).*
- *Hyperglycemia or hypoglycemia with changes in insulin regimen:* Make changes to a patient's insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) under close medical supervision with increased frequency of blood glucose monitoring (5.2).
- *Hypoglycemia:* May be life-threatening. Increase frequency of glucose monitoring with changes to: insulin dosage, concomitantly administered glucose lowering medications, meal pattern, physical activity; and in patients with renal or hepatic impairments and hypoglycemia unawareness (5.3).
- *Medication Errors:* Accidental mix-ups between insulin products can occur. Instruct patients to check insulin labels before injection (5.4).
- *Hypersensitivity reactions:* Severe, life-threatening, generalized allergy, including anaphylaxis, may occur. Discontinue Garzulys, treat, and monitor, if indicated (5.5).
- *Hypokalemia:* May be life-threatening. Monitor potassium levels in patients at risk of hypokalemia and treat if indicated (5.6).
- *Fluid retention and heart failure with concomitant use of thiazolidinediones (TZDs):* Observe for signs and symptoms of heart failure; consider dosage reduction or discontinuation if heart failure occurs (5.7).
- *Hyperglycemia and Ketoacidosis Due to Insulin Pump Device Malfunction:* Monitor glucose and administer Garzulys by subcutaneous injection if pump malfunction occurs (5.8).

ADVERSE REACTIONS

Adverse reactions observed with insulin aspart products include: hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus (6).

To report SUSPECTED ADVERSE REACTIONS, contact Meitheal Pharmaceuticals Inc. at 1-844- 824-8426 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- *Drugs that may increase the risk of hypoglycemia:* antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics (7).
- *Drugs that may decrease the blood glucose lowering effect:* atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones (7).
- *Drugs that may increase or decrease the blood glucose lowering effect:* alcohol, beta-blockers, clonidine, lithium salts, and pentamidine (7).
- *Drugs that may blunt the signs and symptoms of hypoglycemia:* beta-blockers, clonidine, guanethidine, and reserpine (7).

See 17 for PATIENT COUNSELING INFORMATION and FDA approved patient labeling.

*Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of Garzulys has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information.

Revised: 07/2026

FULL PRESCRIBING INFORMATION: CONTENTS*

- 1 INDICATIONS AND USAGE**
- 2 DOSAGE AND ADMINISTRATION**
 - 2.1 Important Preparation and Administration Instructions
 - 2.2 Preparation and Administration Instructions for the Approved Routes of Administration
 - 2.3 Dosage Recommendations
 - 2.4 Dosage Modifications for Drug Interactions
 - 2.5 Instructions for Mixing Garzulys with Other Insulins
- 3 DOSAGE FORMS AND STRENGTHS**
- 4 CONTRAINDICATIONS**
- 5 WARNINGS AND PRECAUTIONS**
 - 5.1 Never Share a Garzulys Prefilled Pen between Patients
 - 5.2 Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen
 - 5.3 Hypoglycemia
 - 5.4 Hypoglycemia Due to Medication Errors
 - 5.5 Hypersensitivity Reactions
 - 5.6 Hypokalemia
 - 5.7 Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists
 - 5.8 Hyperglycemia and Ketoacidosis Due to Insulin Pump Device Malfunction
- 6 ADVERSE REACTIONS**
 - 6.1 Clinical Trials Experience
 - 6.2 Immunogenicity
 - 6.3 Post Marketing Experience
- 7 DRUG INTERACTIONS**
- 8 USE IN SPECIFIC POPULATIONS**
 - 8.1 Pregnancy
 - 8.2 Lactation
 - 8.4 Pediatric Use
 - 8.5 Geriatric Use
 - 8.6 Renal Impairment
 - 8.7 Hepatic Impairment
- 10 OVERDOSAGE**
- 11 DESCRIPTION**
- 12 CLINICAL PHARMACOLOGY**
 - 12.1 Mechanism of Action
 - 12.2 Pharmacodynamics
 - 12.3 Pharmacokinetics
- 13 NONCLINICAL TOXICOLOGY**
 - 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
 - 13.2 Animal Toxicology and/or Pharmacology
- 14 CLINICAL STUDIES**
 - 14.1 Overview of Clinical Studies
 - 14.2 Clinical Studies in Adult and Pediatric Patients with Type 1 Diabetes with Subcutaneous Injections
 - 14.3 Clinical Studies in Adults with Type 2 Diabetes with Subcutaneous Injections
 - 14.4 Clinical Studies in Adults and Pediatrics with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion (CSII) by External Pump
 - 14.5 Clinical Studies in Adults with Type 2 Diabetes Using Continuous Subcutaneous Insulin Infusion (CSII) by External Pump
- 16 HOW SUPPLIED/STORAGE AND HANDLING**
 - 16.1 How Supplied
 - 16.2 Recommended Storage
- 17 PATIENT COUNSELING INFORMATION**

*Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

Garzulys™ is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.

2 DOSAGE AND ADMINISTRATION

2.1 Important Preparation and Administration Instructions

- Always check insulin labels before administration [see *Warnings and Precautions* (5.4)].
- Inspect Garzulys visually before use. It should appear clear and colorless. Do not use Garzulys if particulate matter or coloration is seen.
- Use Garzulys prefilled pen with caution in patients with visual impairment who may rely on audible clicks to dial their dose.
- Do **not** mix Garzulys with other insulins when administering using a continuous subcutaneous infusion pump.

2.2 Preparation and Administration Instructions for the Approved Routes of Administration

Subcutaneous Injection

- Inject Garzulys subcutaneously within 5-10 minutes before a meal into the abdominal area, thigh, buttocks or upper arm.
- Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see *Warnings and Precautions* (5.2) and *Adverse Reactions* (6.1, 6.3)].
- Dial the Garzulys prefilled pen in 1-unit increments.
- Generally use Garzulys (administered by subcutaneous injection) in regimens with an intermediate- or long-acting insulin.
- May dilute Garzulys with Insulin Diluting Medium for Garzulys for subcutaneous injection. Diluting one part Garzulys to:
 - Nine parts diluent will yield a concentration one-tenth that of Garzulys (equivalent to U-10).
 - One part diluent will yield a concentration one-half that of Garzulys (equivalent to U-50).

Continuous Subcutaneous Infusion (Insulin Pump)

- Can use this Garzulys product with the continuous subcutaneous insulin infusion pumps labeled for use with Garzulys or NOVOLOG. Refer to the insulin pump user manual to see if Garzulys or NOVOLOG can be used with the insulin pump, in which case Garzulys can be used with the pump. Use Garzulys in accordance with the insulin pump system's instructions for use.
- Train patients using continuous subcutaneous insulin infusion pump therapy to administer insulin by injection and have alternate insulin therapy available in case of pump failure.
- Administer Garzulys by continuous subcutaneous infusion in a region recommended in the instructions from the pump manufacturer. Rotate infusion sites within the same region to reduce the risk of lipodystrophy or localized cutaneous amyloidosis [see *Warnings and Precautions* (5.2) and *Adverse Reactions* (6.1, 6.3)].
- Instruct patients to follow healthcare provider recommendations when setting basal and meal time infusion rate.
- Change the Garzulys in the reservoir at least every 7 days or according to the pump user manual, whichever is shorter. Follow the Garzulys-specific information for in-use time because Garzulys-specific information may differ from general pump manual instructions.
- Change the infusion set and the infusion set insertion site according to the manufacturer's user manual.
- Do **not** dilute or mix Garzulys when administering by continuous subcutaneous infusion.
- Do **not** expose Garzulys in the pump reservoir to temperatures greater than 98.6°F (37°C).

Intravenous Administration

- Administer Garzulys intravenously **only** under medical supervision with close monitoring of blood glucose and potassium levels to avoid hypoglycemia and hypokalemia [see *Warnings and Precautions* (5.3, 5.6) and *How Supplied/Storage and Handling* (16.2)].
- Dilute Garzulys to concentrations from 0.05 unit per mL to 1 unit per mL insulin aspart-fsan in infusion systems using polypropylene infusion bags. Garzulys is stable in infusion fluids such as 0.9% Sodium Chloride Injection, USP.

2.3 Dosage Recommendations

- Individualize the dosage of Garzulys based on the route of administration, the patient's metabolic needs, blood glucose monitoring results and glycemic control goal.
- Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), changes in renal or hepatic function or during acute illness [see *Warnings and Precautions* (5.2, 5.3) and *Use in Specific Populations* (8.6, 8.7)].
- When switching from another insulin to Garzulys, a different dosage of Garzulys may be needed [see *Warnings and Precautions* (5.2)].
- During changes to a patient's insulin regimen, increase the frequency of blood glucose monitoring [see *Warnings and Precautions* (5.2)].

2.4 Dosage Modifications for Drug Interactions

Dosage modification may be needed when Garzulys is used concomitantly with certain drugs [see *Drug Interactions* (7)].

2.5 Instructions for Mixing Garzulys with Other Insulins

The table below includes instructions regarding mixing Garzulys with other insulins.

Subcutaneous injection route	• Garzulys may only be mixed with NPH insulin preparations. • If Garzulys is mixed with NPH insulin, withdraw Garzulys into the syringe first and inject immediately after mixing.
Continuous subcutaneous infusion route (Insulin Pump)	Do not mix Garzulys with any other insulin.

3 DOSAGE FORMS AND STRENGTHS

Injection: 100 units/mL (U-100) is a clear and colorless solution available as:

- 10 mL multiple-dose vial
- 3 mL single-patient-use prefilled pen

4 CONTRAINDICATIONS

Garzulys is contraindicated:

- During episodes of hypoglycemia [see *Warnings and Precautions* (5.3)]
- In patients with hypersensitivity to insulin aspart products or any of the excipients in Garzulys [see *Warnings and Precautions* (5.5)]

5 WARNINGS AND PRECAUTIONS

5.1 Never Share a Garzulys Prefilled Pen between Patients

Garzulys Prefilled Pen should never be shared between patients, even if the needle is changed. Patients using Garzulys vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.

5.2 Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen

Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) may affect glycemic control and predispose to hypoglycemia [see *Warnings and Precautions* (5.3)] or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia [see *Adverse Reactions* (6.1, 6.3)].

Make any changes to a patient's insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. For patients with type 2 diabetes, dosage adjustments of concomitant anti-diabetic products may be needed.

5.3 Hypoglycemia

Hypoglycemia is the most common adverse reaction of all insulins, including insulin aspart products. Severe hypoglycemia can cause seizures, may lead to unconsciousness, may be life threatening or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery).

Hypoglycemia can happen suddenly and symptoms may differ in each individual and change over time in the same individual. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes in patients with diabetic nerve disease, in patients using medications that block the sympathetic nervous system (e.g., beta-blockers) [see *Drug Interactions* (7)], or in patients who experience recurrent hypoglycemia.

Risk Factors for Hypoglycemia

The risk of hypoglycemia after an injection is related to the duration of action of the insulin and, in general, is highest when the glucose lowering effect of the insulin is maximal. As with all insulins, the glucose lowering effect time course of insulin aspart products may vary in different individuals or at different times in the same individual and depends on many conditions, including the area of injection as well as the injection site blood supply and temperature [see *Clinical Pharmacology* (12.2)]. Other factors which may increase the risk of hypoglycemia include changes in meal pattern (e.g., macronutrient content or timing of meals), changes in level of physical activity, or changes to concomitantly administered medication [see *Drug Interactions* (7)]. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia [see *Use in Specific Populations* (8.6, 8.7)].

Risk Mitigation Strategies for Hypoglycemia

Patients and caregivers must be educated to recognize and manage hypoglycemia. Self-monitoring of blood glucose plays an essential role in the prevention and management of hypoglycemia; increased frequency of blood glucose monitoring is recommended. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia; increased frequency of blood glucose monitoring is recommended.

5.4 Hypoglycemia Due to Medication Errors

Accidental mix-ups between insulin products have been reported. To avoid medication errors between Garzulys and other insulins, instruct patients to always check the insulin label before each injection.

5.5 Hypersensitivity Reactions

Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulins, including insulin aspart products. If hypersensitivity reactions occur, discontinue Garzulys; treat per standard of care and monitor until symptoms and signs resolve [see *Adverse Reactions* (6)]. Garzulys is contraindicated in patients who have had hypersensitivity reactions to insulin aspart products or any of the excipients in Garzulys [see *Contraindications* (4)].

5.6 Hypokalemia

All insulins, including insulin aspart products, can cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia if indicated (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentration).

5.7 Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists

Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. Patients treated with insulin, including Garzulys, and a PPAR-gamma agonist should be observed for signs and symptoms of heart failure. If heart failure develops, it should be managed according to current standards of care, and discontinuation or dose reduction of the PPAR-gamma agonist must be considered.

5.8 Hyperglycemia and Ketoacidosis Due to Insulin Pump Device Malfunction

Malfunction of the insulin pump or insulin infusion set or insulin degradation can rapidly lead to hyperglycemia and ketoacidosis. Prompt identification and correction of the cause of hyperglycemia or ketosis is necessary. Interim subcutaneous injections with Garzulys may be required. Patients using continuous subcutaneous insulin infusion pump therapy must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure [see *How Supplied/Storage and Handling* (16.2) and *Patient Counseling Information* (17)].

6 ADVERSE REACTIONS

The following adverse reactions are also discussed elsewhere:

- Hypoglycemia [see *Warnings and Precautions* (5.3)]
- Hypoglycemia Due to Medication Errors [see *Warnings and Precautions* (5.4)]
- Hypersensitivity Reactions [see *Warnings and Precautions* (5.5)]
- Hypokalemia [see *Warnings and Precautions* (5.6)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying designs, the adverse reaction rates reported in one clinical trial may not be easily compared to those rates reported in another clinical trial, and may not reflect the rates actually observed in clinical practice. The safety of insulin aspart was evaluated in two treat-to-target trials of 6 months duration, conducted in patients with type 1 diabetes or type 2 diabetes [see *Clinical Studies* (14)].

The data in Table 1 reflect the exposure of 596 patients with type 1 diabetes to insulin aspart in one clinical trial with a mean exposure duration to insulin aspart of 24 weeks. The mean age was 39 years. Fifty-one percent were male, 94% were Caucasian, 2% were Black and 4% were other races. The mean body mass index (BMI) was 25.6 kg/m². The mean duration of diabetes was 15.7 years and the mean HbA_{1c} at baseline was 7.9%.

The data in Table 2 reflect the exposure of 91 patients with type 2 diabetes to insulin aspart in one clinical trial with a mean exposure duration to insulin aspart of 24 weeks. The mean age was 57 years. Sixty-three percent were male, 76% were Caucasian, 9% were Black and 15% were other races. The mean BMI was 29.7 kg/m². The mean duration of diabetes was 12.7 years and the mean HbA_{1c} at baseline was 8.1%.

Common adverse reactions were defined as events that occurred in ≥5%, excluding hypoglycemia, of the population studied. Common adverse events that occurred at the same rate or greater for insulin aspart-treated patients than in comparator-treated patients during clinical trials in patients with type 1 diabetes mellitus and type 2 diabetes mellitus (other than hypoglycemia) are listed in Table 1 and Table 2, respectively.

Table 1: Adverse reactions that occurred in $\geq 5\%$ of Type 1 Diabetes Mellitus Adult Patients treated with insulin aspart and at the same rate or greater on insulin aspart than on comparator

	Insulin Aspart + NPH (%) (n= 596)	Regular Human Insulin + NPH (%) (n= 286)
Headache	12	10
Injury accidental	11	10
Nausea	7	5
Diarrhea	5	3

Table 2: Adverse reactions that occurred in $\geq 5\%$ of Type 2 Diabetes Mellitus Adult Patients treated with Insulin Aspart and at the same rate or greater on Insulin Aspart than on comparator

	Insulin Aspart + NPH (%) (n= 91)	Human Regular Insulin + NPH (%) (n= 91)
Hyporeflexia	11	7
Onychomycosis	10	5
Sensory disturbance	9	7
Urinary tract infection	8	7
Chest pain	5	3
Headache	5	3
Skin disorder	5	2
Abdominal pain	5	1
Sinusitis	5	1

Severe Hypoglycemia

Hypoglycemia is the most commonly observed adverse reaction in patients using insulin, including insulin aspart products. The rates of reported hypoglycemia depend on the definition of hypoglycemia used, diabetes type, insulin dose, intensity of glucose control, background therapies, and other intrinsic and extrinsic patient factors. For these reasons, comparing rates of hypoglycemia in clinical trials for insulin aspart with the incidence of hypoglycemia for other products may be misleading and also, may not be representative of hypoglycemia rates that will occur in clinical practice.

Severe hypoglycemia was defined as hypoglycemia associated with central nervous system symptoms and requiring the intervention of another person or hospitalization. The incidence of severe hypoglycemia in:

- Adult and pediatric patients with type 1 diabetes mellitus who received subcutaneous insulin aspart was 17% at 24 weeks and 6% at 24 weeks, respectively [see *Clinical Studies (14)*].
- Adult patients with type 2 diabetes mellitus who received subcutaneous insulin aspart was 10% at 24 weeks.
- Adult and pediatric patients with type 1 diabetes mellitus, who received insulin aspart via continuous subcutaneous insulin infusion by external pump was 2% at 16 weeks and 10% at 16 weeks respectively.

No severe hypoglycemic episodes were reported in adult patients with type 2 diabetes mellitus receiving Insulin Aspart via continuous subcutaneous insulin infusion by external pump at 16 weeks.

Allergic Reactions

Some patients taking insulin, including insulin aspart products have experienced erythema, local edema, and pruritus at the site of injection. These conditions were usually self-limiting. Severe cases of generalized allergy (anaphylaxis) have been reported.

Adverse Reactions Associated with Insulin Initiation and Glucose Control Intensification

Intensification or rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic refraction disorder, worsening of diabetic retinopathy, and acute painful peripheral neuropathy. However, long-term glycemic control decreases the risk of diabetic retinopathy and neuropathy.

Lipodystrophy

Administration of insulin, including insulin aspart products, subcutaneously and via subcutaneous insulin infusion by external pump, has resulted in lipoatrophy (depression in the skin) or lipohypertrophy (enlargement or thickening of tissue) in some patients [see *Dosage and Administration* (2.2)].

Peripheral Edema

Insulins, including insulin aspart products, may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy.

Weight Gain

Weight gain has occurred with insulins, including insulin aspart products, and has been attributed to the anabolic effects of insulin and the decrease in glucosuria.

6.2 Immunogenicity

As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other insulin aspart products may be misleading.

In a 6-month study with a 6-month extension in adult subjects with type 1 diabetes, 99.8% of patients who received Insulin Aspart were positive for anti-insulin antibodies (AIA) at least once during the study, including 97.2% that were positive at baseline. A total of 92.1% of patients who received Insulin Aspart were positive for anti-drug antibodies (ADA) at least once during the study, including 64.6% that were positive at baseline.

In a phase 3 type 1 diabetes clinical trial of Insulin Aspart, initial increase in titers of antibodies to insulin, followed by a decrease to baseline values, was observed in regular human insulin and insulin aspart treatment groups with similar incidences. These antibodies did not cause deterioration in glycemic control or necessitate increases in insulin dose.

6.3 Post Marketing Experience

The following adverse reactions have been identified during post-approval use of insulin aspart products. Because these adverse reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Medication errors have been reported in which other insulins have been accidentally substituted for insulin aspart products.

Localized cutaneous amyloidosis at the injection site has occurred with insulin aspart products. Hyperglycemia has been reported with repeated insulin injections into areas of localized cutaneous amyloidosis; hypoglycemia has been reported with a sudden change to an unaffected injection site.

7 DRUG INTERACTIONS

The table below presents clinically significant drug interactions with Garzulys.

Drugs That May Increase the Risk of Hypoglycemia	
<i>Drugs:</i>	Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics.
<i>Intervention:</i>	Dose adjustment and increased frequency of glucose monitoring may be required when Garzulys is concomitantly administered with these drugs.
Drugs That May Decrease the Blood Glucose Lowering Effect of Garzulys	
<i>Drugs:</i>	Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.
<i>Intervention:</i>	Dose adjustment and increased frequency of glucose monitoring may be required when Garzulys is concomitantly administered with these drugs.
Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of Garzulys	
<i>Drugs:</i>	Alcohol, beta-blockers, clonidine, and lithium salts. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.
<i>Intervention:</i>	Dose adjustment and increased frequency of glucose monitoring may be required when Garzulys is concomitantly administered with these drugs.
Drugs That May Blunt Signs and Symptoms of Hypoglycemia	
<i>Drugs:</i>	Beta-blockers, clonidine, guanethidine and reserpine
<i>Intervention:</i>	Increased frequency of glucose monitoring may be required when Garzulys is concomitantly administered with these drugs.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Available information from published randomized controlled trials with insulin aspart products use during the second trimester of pregnancy have not reported an association with insulin aspart products and major birth defects or adverse maternal or fetal outcomes [see Data]. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy [see Clinical Considerations].

In animal reproduction studies, administration of subcutaneous insulin aspart to pregnant rats and rabbits during the period of organogenesis did not cause adverse developmental effects at exposures 8-times and equal to the human subcutaneous dose of 1 unit/kg/day, respectively. Pre- and post-implantation losses and visceral/skeletal abnormalities were seen at higher exposures, which are considered secondary to maternal hypoglycemia. These effects were similar to those observed in rats administered regular human insulin [see Data].

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. The estimated background risk of major birth defects is 6 to 10% in women with pre-gestational diabetes with a periconceptual HbA_{1c} >7% and has been reported to be as high as 20 to 25% in women with a periconceptual HbA_{1c} >10%. The estimated background risk of miscarriage for the indicated population is unknown.

Clinical Considerations

Disease-Associated Maternal and/or Embryo-Fetal Risk

Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery, and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity.

Data

Human Data

Published data from 5 randomized controlled trials of 441 pregnant women with diabetes mellitus treated with insulin aspart products during the late 2nd trimester of pregnancy did not identify an association of insulin aspart products with major birth defects or adverse maternal or fetal outcomes. However, these studies cannot definitely establish the absence of any risk because of methodological limitations, including a variable duration of treatment and small size of the majority of the trials.

Animal Data

Fertility, embryo-fetal and pre- and postnatal development studies have been performed with insulin aspart and regular human insulin in rats and rabbits. In a combined fertility and embryo-fetal development study in rats, insulin aspart was administered before mating, during mating, and throughout pregnancy. Further, in a pre- and postnatal development study insulin aspart was given throughout pregnancy and during lactation to rats. In an embryo-fetal development study insulin aspart was given to female rabbits during organogenesis. The effects of insulin aspart did not differ from those observed with subcutaneous regular human insulin. Insulin aspart, like human insulin, caused pre- and post-implantation losses and visceral/skeletal abnormalities in rats at a dose of 200 units/kg/day (approximately 32 times the human subcutaneous dose of 1 unit/kg/day, based on human exposure equivalents) and in rabbits at a dose of 10 units/kg/day (approximately three times the human subcutaneous dose of 1 unit/kg/day, based on human exposure equivalents). No significant effects were observed in rats at a dose of 50 units/kg/day and in rabbits at a dose of 3 units/kg/day. These doses are approximately 8 times the human subcutaneous dose of 1 unit/kg/day for rats and equal to the human subcutaneous dose of 1 unit/kg/day for rabbits, based on human exposure equivalents. The effects are considered secondary to maternal hypoglycemia.

8.2 Lactation

Risk Summary

There are no data on the presence of insulin aspart products in human milk, the effects on the breastfed infant, or the effect on milk production. One small published study reported that exogenous insulin, including insulin aspart, was present in human milk. However, there is insufficient information to determine the effects of insulin aspart products on the breastfed infant. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Garzulyls, and any potential adverse effects on the breastfed infant from Garzulyls, or from the underlying maternal condition.

8.4 Pediatric Use

The safety and effectiveness of Garzulyls to improve glycemic control have been established in pediatric patients with diabetes mellitus. Use of Garzulyls for this indication is supported by evidence from an adequate and well-controlled study of insulin aspart in 283 pediatric patients with type 1 diabetes mellitus aged 6 to 18 years and from studies in adults with diabetes mellitus [see *Adverse Reactions* (6.1), *Clinical Pharmacology* (12.3), and *Clinical Studies* (14)].

8.5 Geriatric Use

Of the total number of patients (n=1,375) treated with insulin aspart in 3 controlled clinical studies, 2.6% (n=36) were 65 years of age or over. One-half of these patients had type 1 diabetes (18/1285) and the other half had type 2 diabetes (18/90). The HbA_{1c} response to insulin aspart, as compared to regular human insulin, did not differ by age.

8.6 Renal Impairment

Patients with renal impairment may be at increased risk of hypoglycemia and may require more frequent Garzulyls dose adjustment and more frequent blood glucose monitoring [see *Warnings and Precautions* (5.3) and *Clinical Pharmacology* (12.3)].

8.7 Hepatic Impairment

Patients with hepatic impairment may be at increased risk of hypoglycemia and may require more frequent Garzulys dose adjustment and more frequent blood glucose monitoring [see *Warnings and Precautions* (5.3) and *Clinical Pharmacology* (12.3)].

10 OVERDOSAGE

Excess insulin administration may cause hypoglycemia and hypokalemia [see *Warnings and Precautions* (5.3, 5.6)]. Mild episodes of hypoglycemia usually can be treated with oral glucose. Adjustments in drug dosage, meal patterns, or exercise may be needed. More severe episodes with coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycemia may recur after apparent clinical recovery. Hypokalemia must be corrected appropriately.

11 DESCRIPTION

Insulin aspart-fsan is a rapid-acting human insulin analog homologous with regular human insulin with the exception of a single substitution of the amino acid proline by aspartic acid in position B28, and is produced by recombinant DNA technology utilizing *Escherichia coli*. Insulin aspart-fsan has the empirical formula $C_{256}H_{381}N_{65}O_{79}S_6$ and a molecular weight of 5825.8 Da.




Figure 1. Structural formula of insulin aspart-fsan.

Garzulys (insulin aspart-fsan) injection is a sterile, clear, and colorless solution for subcutaneous or intravenous use. Each mL contains 100 units of insulin aspart-fsan and the inactive ingredients: dibasic sodium phosphate (0.997 mg), glycerin (16 mg), metacresol (1.72 mg), phenol (1.5 mg), sodium chloride (0.58 mg), zinc (19.6 mcg), and Water for Injection, USP. Garzulys has a pH of 7.2-7.6. Hydrochloric acid and/or sodium hydroxide may be added to adjust pH.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The primary activity of insulin, including insulin aspart products, is the regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.

12.2 Pharmacodynamics

Pharmacodynamics of Insulin Aspart After Subcutaneous Administration

The pharmacodynamic profile of insulin aspart given subcutaneously in 22 patients with type 1 diabetes is shown in Figure

2. The maximum glucose-lowering effect of insulin aspart occurred between 1 and 3 hours after subcutaneous injection (0.15 units/kg). The duration of action for insulin aspart is 3 to 5 hours. The time course of action of insulin and insulin analogs such as insulin aspart products may vary considerably in different individuals or within the same individual. The parameters of insulin aspart activity (time of onset, peak time and duration) as designated in Figure 2 should be considered only as general guidelines. The rate of insulin absorption and onset of activity is affected by the site of injection, exercise, and other variables [see *Warnings and Precautions* (5.3)].





Figure 2. Serial mean serum glucose collected up to 6 hours following a single 0.15 units/kg pre-meal dose of insulin aspart (solid curve) or regular human insulin (hatched curve) injected immediately before a meal in 22 patients with type 1 diabetes.

Pharmacodynamics of Insulin Aspart After Intravenous Administration

A double-blind, randomized, two-way crossover study in 16 patients with type 1 diabetes demonstrated that intravenous infusion of insulin aspart resulted in a blood glucose profile that was similar to that after intravenous infusion with regular human insulin. Insulin aspart or human insulin was infused until the patient's blood glucose decreased to 36 mg/dL, or until the patient demonstrated signs of hypoglycemia (rise in heart rate and onset of sweating), defined as the time of autonomic reaction (R) (see Figure 3).



Note: The slashes on the mean profile indicate a jump on the time axis

Figure 3. Mean blood glucose profiles following intravenous infusion of insulin aspart (hatched curve) and regular human insulin (solid curve) in 16 patients with type 1 diabetes. R represents the time of autonomic reaction.

12.3 Pharmacokinetics

Pharmacokinetics of subcutaneous administration of insulin aspart is presented below.

Absorption and Bioavailability

In studies in healthy volunteers (total n=107) and patients with type 1 diabetes (total n=40), the median time to maximum concentration of insulin aspart in these trials was 40 to 50 minutes versus 80 to 120 minutes, for regular human insulin respectively.

The relative bioavailability of insulin aspart (0.15 units/kg) compared to regular human insulin indicates that the two insulins are absorbed to a similar extent.

In a clinical trial in patients with type 1 diabetes, insulin aspart and regular human insulin, both administered subcutaneously at a dose of 0.15 units/kg body weight, reached mean maximum concentrations of 82 and 36 mU/L, respectively.

Distribution

Insulin aspart has a low binding affinity to plasma proteins (<10%), similar to that seen with regular human insulin.




Figure 4. Serial mean serum free insulin concentration collected up to 6 hours following a single 0.15 units/kg pre-meal dose of insulin aspart (solid curve) or regular human insulin (hatched curve) injected immediately before a meal in 22 patients with type 1 diabetes.

Metabolism and Elimination

In a randomized, double-blind, crossover study 17 healthy Caucasian male subjects between 18 and 40 years of age received an intravenous infusion of either insulin aspart or regular human insulin at 1.5 mU/kg/min for 120 minutes. The mean insulin clearance was similar for the two groups with mean values of 1.2 L/h/kg for the insulin aspart group and 1.2 L/h/kg for the regular human insulin group.

After subcutaneous administration in normal male volunteers (n=24), insulin aspart was eliminated with an average apparent half-life of 81 minutes.

Specific Populations

Pediatric Patients

The pharmacokinetic and pharmacodynamic properties of insulin aspart and regular human insulin were evaluated in a

single dose study in 18 pediatric patients with type 1 diabetes in 2 age groups: 6-12 years, n=9 and 13-17 years (Tanner grade ≥ 2), n=9. The relative differences in pharmacokinetics and pharmacodynamics in the pediatric patients with type 1 diabetes in both age groups between insulin aspart and regular human insulin were similar to those in healthy adult subjects and adults with type 1 diabetes.

Geriatric Patients

The pharmacokinetic and pharmacodynamic properties of insulin aspart and regular human insulin were investigated in a single dose study in 18 subjects with type 2 diabetes who were ≥ 65 years of age. The relative differences in pharmacokinetics and pharmacodynamics in geriatric patients with type 2 diabetes between insulin aspart and regular human insulin were similar to those in younger adults.

Male and Female Patients

In healthy volunteers given a single subcutaneous dose of insulin aspart 0.06 units/kg, no difference in insulin aspart levels was seen between males and females based on comparison of $AUC_{(0-10h)}$ or C_{max} .

Obese Patients

A single subcutaneous dose of 0.1 units/kg insulin aspart was administered in a study of 23 patients with type 1 diabetes and a wide range of body mass index (BMI, 22-39 kg/m²). The pharmacokinetic parameters, AUC and C_{max} , of insulin aspart were generally unaffected by BMI in the different groups – BMI 19-23 kg/m² (n=4); BMI 23-27 kg/m² (n=7); BMI 27-32 kg/m² (n=6) and BMI >32 kg/m² (n=6). Clearance of insulin aspart was reduced by 28% in patients with BMI >32 kg/m² compared to patients with BMI <23 kg/m².

Patients with Renal Impairment

A single subcutaneous dose of 0.08 units/kg insulin aspart was administered in a study to subjects with either normal renal function (n=6) creatinine clearance (CLcr) (> 80 mL/min) or mild (n=7; CLcr = 50-80 mL/min), moderate (n=3; CLcr = 30-50 mL/min) or severe (but not requiring hemodialysis) (n=2; CLcr = <30 mL/min) renal impairment. In this study, there was no apparent effect of creatinine clearance values on AUC and C_{max} of insulin aspart.

Patients with Hepatic Impairment

A single subcutaneous dose of 0.06 units/kg insulin aspart was administered in an open-label, single-dose study of 24 subjects (n=6/group) with different degree of hepatic impairment (mild, moderate and severe) having Child-Pugh Scores ranging from 0 (healthy volunteers) to 12 (severe hepatic impairment). In this study, there was no correlation between the degree of hepatic impairment and any insulin aspart pharmacokinetic parameter.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Standard 2-year carcinogenicity studies in animals have not been performed to evaluate the carcinogenic potential of insulin aspart products. In 52-week studies, Sprague-Dawley rats were dosed subcutaneously with insulin aspart at 10, 50, and 200 units/kg/day (approximately 2, 8, and 32 times the human subcutaneous dose of 1.0 units/kg/day, based on units/body surface area, respectively). At a dose of 200 units/kg/day, insulin aspart increased the incidence of mammary gland tumors in females when compared to untreated controls. The relevance of these findings to humans is unknown.

Insulin aspart was not genotoxic in the following tests: Ames test, mouse lymphoma cell forward gene mutation test, human peripheral blood lymphocyte chromosome aberration test, *in vivo* micronucleus test in mice, and *in ex vivo* UDS test in rat liver hepatocytes.

In fertility studies in male and female rats, at subcutaneous doses up to 200 units/kg/day (approximately 32 times the human subcutaneous dose, based on units/body surface area), no direct adverse effects on male and female fertility, or general reproductive performance of animals was observed.

13.2 Animal Toxicology and/or Pharmacology

In standard biological assays in mice and rabbits, one unit of insulin aspart has the same glucose-lowering effect as one unit of regular human insulin.

14 CLINICAL STUDIES

14.1 Overview of Clinical Studies

The safety and effectiveness of subcutaneous insulin aspart were compared to regular human insulin in 596 type 1 diabetes adult, 187 pediatric type 1 diabetes, and 91 adult type 2 diabetes patients using NPH as basal insulin (see Tables 3, 4, 5). The reduction in glycated hemoglobin (HbA_{1c}) was similar to regular human insulin.

The safety and effectiveness of insulin aspart administered by continuous subcutaneous insulin infusion (CSII) by external pump were compared to buffered regular human insulin (administered by CSII), to lispro (administered by CSII) and compared to insulin aspart injections and NPH injection. Overall, the reduction in HbA_{1c} was similar to the comparator.

14.2 Clinical Studies in Adult and Pediatric Patients with Type 1 Diabetes with Subcutaneous Injections

Type 1 Diabetes - Adults (see Table 3)

Two 24-week, open-label, active-controlled studies were conducted to compare the safety and efficacy of insulin aspart to regular human insulin injection in adult patients with type 1 diabetes. Because the two study designs and results were similar, data are shown for only one study (see Table 3).

The mean age of the trial population was 39 years and mean duration of diabetes was 15.7 years. Fifty-one percent were male. Ninety-four percent were Caucasian, 2% were Black and 4% were Other. The mean BMI was approximately 25.6 kg/m².

Insulin aspart was administered by subcutaneous injection immediately prior to meals and regular human insulin was administered by subcutaneous injection 30 minutes before meals. NPH insulin was administered as the basal insulin in either single or divided daily doses. Changes in HbA_{1c} were comparable for the two treatment regimens in this study (Table 3).

Table 3. Type 1 Diabetes Mellitus – Adult (Insulin Aspart plus NPH insulin vs. regular human insulin plus NPH insulin)

	Insulin Aspart + NPH (n=596)	Regular Human Insulin+ NPH (n=286)
Baseline HbA _{1c} (%)*	7.9 ± 1.1	8.0 ± 1.2
Change from Baseline HbA _{1c} (%)	-0.1 ± 0.8	0.0 ± 0.8
Treatment Difference in HbA _{1c} , Mean (95% confidence interval)	-0.2 (-0.3, -0.1)	

*Values are Mean ± SD

Type 1 Diabetes – Pediatric (see Table 4)

The efficacy of insulin aspart to improve glycemic control in pediatric patients with type 1 diabetes mellitus is based on an adequate and well-controlled trial of regular human insulin in pediatric patients with type 1 diabetes mellitus (Table 4). This 24-week, parallel-group study of pediatric patients with type 1 diabetes (n=283), aged 6 to 18 years, compared two subcutaneous multiple-dose treatment regimens: insulin aspart (n=187) or regular human insulin (n=96). NPH insulin was administered as the basal insulin. Similar effects on HbA_{1c} were observed in both treatment groups (Table 4).

Subcutaneous administration of insulin aspart and regular human insulin have also been compared in pediatric patients with type 1 diabetes (n=26) aged 2 to 6 years with similar effects on HbA_{1c}.

Table 4. Pediatric Subcutaneous Administration of Insulin Aspart in Type 1 Diabetes (24 weeks; n=283)

	Insulin Aspart + NPH (n=187)	Regular Human Insulin+ NPH (n=96)
Baseline HbA _{1c} (%)*	8.3 ± 1.2	8.3 ± 1.3
Change from Baseline HbA _{1c} (%)	0.1 ± 1.0	0.1 ± 1.1
Treatment Difference in HbA _{1c} , Mean (95% confidence interval)	-0.2 (-0.5, 0.1)	

*Values are Mean ± SD

14.3 Clinical Studies in Adults with Type 2 Diabetes with Subcutaneous Injections

Type 2 Diabetes - Adults (see Table 5)

One six-month, open-label, active-controlled study was conducted to compare the safety and efficacy of insulin aspart to regular human insulin in patients with type 2 diabetes (Table 5).

The mean age of the trial population was 56.6 years and mean duration of diabetes was 12.7 years. Sixty-three percent were male. Seventy-six percent were Caucasian, 9% were Black and 15% were Other. The mean BMI was approximately 29.7 kg/m².

Insulin aspart was administered by subcutaneous injection immediately prior to meals and regular human insulin was administered by subcutaneous injection 30 minutes before meals. NPH insulin was administered as the basal insulin in either single or divided daily doses. Changes in HbA_{1c} were comparable for the two treatment regimens.

Table 5. Subcutaneous Insulin Aspart Administration in Type 2 Diabetes (6 months; n=176)

	Insulin Aspart + NPH (n=90)	Regular Human Insulin + NPH (n=86)
Baseline HbA _{1c} (%)*	8.1 ± 1.2	7.8 ± 1.1
Change from Baseline HbA _{1c} (%)	-0.3 ± 1.0	-0.1 ± 0.8
Treatment Difference in HbA _{1c} , Mean (95% confidence interval)	- 0.1 (-0.4, 0.1)	

*Values are Mean ± SD

14.4 Clinical Studies in Adults and Pediatrics with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion (CSII) by External Pump

Type 1 Diabetes – Adult (see Table 6)

Two open-label, parallel design studies (6 weeks [n=29] and 16 weeks [n=118]) compared insulin aspart to buffered regular human insulin (Velosulin) in adults with type 1 diabetes receiving a subcutaneous infusion with an external insulin pump.

The mean age of the trial population was 42.3 years. Thirty-nine percent were male. Ninety-eight percent were Caucasian

and 2% were Black.

The two treatment regimens had comparable changes in HbA_{1c}.

Table 6. Adult Insulin Pump Study in Type 1 Diabetes (16 weeks; n=118)

	Insulin Aspart (n=59)	Buffered human insulin (n=59)
Baseline HbA _{1c} (%)*	7.3 ± 0.7	7.5 ± 0.8
Change from Baseline HbA _{1c} (%)	0.0 ± 0.5	0.2 ± 0.6
Treatment Difference in HbA _{1c} , Mean (95% confidence interval)	0.2 (-0.1, 0.4)	

*Values are Mean ± SD

Type 1 Diabetes – Pediatric (see Table 7)

A randomized, 16-week, open-label, parallel design study of pediatric patients with type 1 diabetes (n=298) aged 4-18 years compared two subcutaneous infusion regimens administered via an external insulin pump: insulin aspart (n=198) or insulin lispro (n=100). These two treatments resulted in comparable changes from baseline in HbA_{1c} (see Table 7).

Table 7. Pediatric Insulin Pump Study in Type 1 Diabetes (16 weeks; n=298)

	Insulin Aspart (n=198)	Lispro (n=100)
Baseline HbA _{1c} (%)*	8.0 ± 0.9	8.2 ± 0.8
Change from Baseline HbA _{1c} (%)	-0.1 ± 0.8	-0.1 ± 0.7
Treatment Difference in HbA _{1c} , Mean (95% confidence interval)	-0.1 (-0.3, 0.1)	

*Values are Mean ± SD

14.5 Clinical Studies in Adults with Type 2 Diabetes Using Continuous Subcutaneous Insulin Infusion (CSII) by External Pump

Type 2 Diabetes – Adults (see Table 8)

An open-label, 16-week parallel design trial compared pre-prandial insulin aspart injection in conjunction with NPH injections to insulin aspart administered by continuous subcutaneous infusion in 127 adults with type 2 diabetes.

The mean age of the trial population was 55.1 years. Sixty-four percent were male. Eighty percent were Caucasian, 12% were Black and 8% were Other. The mean BMI was approximately 32.2 kg/m².

The two treatment groups had similar reductions in HbA_{1c} (Table 8).

Table 8. Pump Therapy in Type 2 Diabetes (16 weeks; n=127)

	Insulin Aspart pump (n=66)	Insulin Aspart + NPH (n=61)

Baseline HbA _{1c} (%)*	8.2 ± 1.4	8.0 ± 1.1
Change from Baseline HbA _{1c} (%)	-0.6 ± 1.1	-0.5 ± 0.9
Treatment Difference in HbA _{1c} , Mean (95% confidence interval)	0.1 (-0.3, 0.4)	

*Values are Mean ± SD

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

Garzulys (insulin aspart-fsan) injection 100 units/mL (U-100) is available as a clear and colorless solution and is supplied as follows:

Garzulys (insulin aspart-fsan) Injection 100 units/mL (U-100)	Package Size	NDC
10 mL Multiple-Dose Vial	1 vial per carton	71288- 904 -10
3 mL prefilled, Single-Patient-Use pen	5 pens per carton	71288- 903 -81

*Garzulys Prefilled Pen can be used with disposable needles, such as, NovoFine or NovoFine Plus.

The Garzulys Prefilled Pen dials in 1-unit increments.

Dispense in the original sealed carton with the enclosed Instructions for Use.

Sterile, Nonpyrogenic.

The container closure is not made with natural rubber latex.

16.2 Recommended Storage

Dispense in the original sealed carton with the enclosed Instructions for Use. Store unused Garzulys in a refrigerator between 2°C to 8°C (36°F to 46°F). Do not freeze Garzulys and do not use Garzulys if it has been frozen. Do not expose Garzulys to excessive heat or light. Do **not** withdraw Garzulys into a syringe and store for later use.

Always remove and discard the needle after each injection from the Garzulys Prefilled Pen and store without a needle attached.

The storage conditions are summarized in the following table:

Table 9. Storage Conditions for Garzulys Vial and Prefilled Pen

Garzulys presentation	Not in-use (unopened) Room Temperature (up to 30°C [86°F])	Not in-use (unopened) Refrigerated (2°C to 8°C [36°F to 46°F])	In-use (opened) Room Temperature (up to 30°C [86°F])
10 mL multiple-dose vial	28 days	Until expiration date	28 days* (refrigerated/room temperature)

3 mL single-patient-use prefilled pen	28 days	Until expiration date	28 days (Do not refrigerate)
---------------------------------------	---------	-----------------------	---------------------------------

***For insulin pump use, the total in-use time is 19 days, including 7 days pump in-use time.**

Storage in External Insulin Pump:

Change Garzulys in the pump reservoir at least every 7 days or according to the pump user manual instructions for Garzulys or NOVLOG, whichever is shorter, or after exposure to temperatures that exceed 37°C (98.6°F).

Storage of Diluted Garzulys

Garzulys diluted with Insulin Diluting Medium for Garzulys to a concentration equivalent to U-10 or equivalent to U-50 prepared as indicated under *Dosage and Administration* (2.2) may remain in patient use at temperatures up to 30°C (86°F) for 28 days.

Storage of Garzulys in Intravenous Infusion Fluids

Infusion bags prepared as indicated under *Dosage and Administration* (2.2) are stable at room temperature for 24 hours. Some insulin will be initially adsorbed to the material of the infusion.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Never Share a Garzulys Prefilled Pen Device between Patients

Advise patients that they must never share a Garzulys prefilled pen with another person even if the needle is changed, because doing so carries a risk for transmission of blood-borne pathogens. Advise patients using Garzulys vials not to share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens [see *Warnings and Precautions* (5.1)].

Hyperglycemia or Hypoglycemia

Inform patients that hypoglycemia is the most common adverse reaction with insulin. Instruct patients on self-management procedures including glucose monitoring, proper injection technique, and management of hypoglycemia and hyperglycemia, especially at initiation of Garzulys therapy. Instruct patients on handling of special situations such as intercurrent conditions (illness, stress, or emotional disturbances), an inadequate or skipped insulin dose, inadvertent administration of an increased insulin dose, inadequate food intake, and skipped meals. Instruct patients on the management of hypoglycemia [see *Warnings and Precautions* (5.3)].

Inform patients that their ability to concentrate and react may be impaired as a result of hypoglycemia. Advise patients who have frequent hypoglycemia or reduced or absent warning signs of hypoglycemia to use caution when driving or operating machinery.

Advise patients that changes in insulin regimen can predispose to hyperglycemia or hypoglycemia and that changes in insulin regimen should be made under close medical supervision [see *Warnings and Precautions* (5.2)].

Hypoglycemia with Medication Errors

Instruct patients to always check the insulin label before each injection to avoid mix-ups between insulin products [see *Warnings and Precautions* (5.3)].

Hypersensitivity Reactions

Advise patients that hypersensitivity reactions have occurred with insulin aspart products. Inform patients of the symptoms

of hypersensitivity reactions [see *Warnings and Precautions* (5.4)].

Patients Using Continuous Subcutaneous Insulin Pumps

- Train patients in both intensive insulin therapy with multiple injections and in the function of their pump and pump accessories.
- This Garzulys product can be used with continuous subcutaneous insulin infusion pumps labeled for use with Garzulys or NOVOLOG - refer to the insulin pump user manual to see if Garzulys or NOVOLOG can be used with the insulin pump, in which case Garzulys can be used with the pump. See recommended infusion sets in the insulin pump user manual.
- Instruct patients to replace insulin in the reservoir at least every 7 days or according to the user manual, whichever is shorter; infusion sets and infusion set insertion sites should be changed according to the manufacturer's user manual. By following this schedule, patients avoid insulin degradation, infusion set occlusion, and loss of the insulin preservative.
- Instruct patients to discard insulin exposed to temperatures higher than 37°C (98.6°F).
- Instruct patients to inform physician and select a new site for infusion if infusion site becomes erythematous, pruritic, or thickened.
- Instruct patients of the risk of rapid hyperglycemia and ketosis due to pump malfunction, infusion set occlusion, leakage, disconnection or kinking, and degraded insulin. If these problems cannot be promptly corrected, instruct patients to resume therapy with subcutaneous insulin injection and contact their physician [see *Warnings and Precautions* (5) and *How Supplied/Storage and Handling* (16.2)].
- Instruct patients of the risk of hypoglycemia from pump malfunction. If these problems cannot be promptly corrected, instruct patients to resume therapy with subcutaneous insulin injection and contact their physician [see *Warnings and Precautions* (5) and *How Supplied/Storage and Handling* (16.2)].

Additional Patient Information Leaflets and Instructions for Use are available at <http://www.meithealpharma.com> or call 1-844-824-8426.

Brands listed are the trademarks of their respective owners.



Manufactured for: Meitheal Pharmaceuticals

Chicago, IL 60631 (USA)

©2026 Meitheal Pharmaceuticals Inc.

Manufactured by: Emerge Bioscience Pte. Ltd.

Singapore 069535

U.S. License Number 2395

Garzulys™ is a registered trademark of Emerge Bioscience Pte. Ltd.